Science's Data Search Engine

Graphical overview — experiment to test whether PD-constipation microbiota drives Th17, CNS thrombin, aSyn truncation, and dopaminergic loss

Design below proposes 4 mouse groups: (1) healthy human-control FMT + PFF, (2) PD-constipation human FMT + PFF, (3) PD-FMT + PFF + thrombin inhibitor, (4) PD-FMT + vehicle — with longitudinal immune (blood/spleen), CNS thrombin activity, aSyn fragment proteomics, and nigral TH quantification (endpoints).

Experiment design + visual data plan

Below: compact, graph-first experimental plan (timelines, group sizes/power, measurements) followed by rationale with precise citations for each mechanistic link used to justify the design.

Concise experimental protocol (components)

1. Animals: adult male C57BL/6J mice (8–10 wks), n = 12–15 per group (see power heuristics). Groups: (A) healthy human-control FMT + PFF; (B) human PD-constipation FMT + PFF; (C) PD-FMT + PFF + thrombin inhibitor; (D) PD-FMT + PFF + vehicle. Randomize and blind endpoints.
2. Microbiota transplant: donor feces pooled from clinically-characterized PD patients with constipation vs matched healthy donors; 5-day antibiotic pretreatment (ampicillin/metronidazole/neomycin/vancomycin) followed by oral gavage FMT for 7 days; confirm engraftment by 16S qPCR/amplicon sequencing (days 0, 14).
3. PFF seeding: unilateral intrastriatal injection of human α-syn PFF (70 nM equivalent, 2–5 µg) at Day 0 to match robust seeding paradigms used in neuronal models and in vivo studies C-term truncation aSyn study.
4. Thrombin inhibition arm: small-molecule PAR1 antagonist or direct thrombin inhibitor (select based on PK/BBB penetration). Administer systemically starting Day -1 and continuing through Week 8; include vehicle control. Rationale: thrombin activates microglia through PAR1 and can modulate neuroinflammation PAR1-thrombin microglial activation.
5. Timepoints & sampling: baseline, Week 2, Week 4, Week 8 (terminal). At each: blood for flow cytometry (Th17, Treg), plasma cytokines (IL-17A, IL-6, IL-1β), feces (microbiome), behavior (rotarod/pole/stride). Terminal: perfuse, collect striatum & SN for biochemical and histology, isolate microglia/astrocytes for thrombin activity assay, immunohistochemistry for pS129 aSyn and TH, and proteomic mapping of α-syn fragments (top-down and bottom-up LC-MS/MS) following protocols used in proteoform mapping studies Appendix aSyn proteoforms TD-MS.

Primary readouts (how each maps to hypothesis)

• Peripheral Th17 response: flow cytometry for CD4+IL-17A+ cells in blood and spleen; ELISA for plasma IL-17A. Justification: PD-associated microbiota or PFF exposures can modulate peripheral T-cell subsets; LAG3 and Treg/Th17 changes influence gut-to-brain spread in PFF models LAG3 Treg PFF study.
• CNS thrombin activity & PAR signaling: biochemical thrombin activity assay in brain lysates; immunoblot/PAR1 expression in microglia/astrocytes; microglial activation markers (Iba1, CD68, CD40). Rationale: thrombin promotes microglial activation via PAR1 and is a plausible mediator linking vascular/peripheral signals to CNS inflammation PAR1 microglia thrombin.
• α-Synuclein truncation mapping: immunoblot with N- and C-terminal antibodies, Tricine gels, and LC-MS/MS top-down and bottom-up to map truncation endpoints (1–114, 1–119, 1–103 etc.) — replicating approaches from neuronal seeding/truncation mapping papers aSyn truncation proteomics.
• Dopaminergic neuron loss / neuropathology: stereological TH+ neuron counts in SN, striatal TH fiber density, pS129 aSyn burden, microglial/astrocyte activation, and behavioral metrics (rotarod/pole). These are the disease-relevant downstream endpoints.

Mechanistic rationale & evidence links (compact, cited)

1) Gut microbiota can drive PD-like phenotypes and modulate CNS metabolism/inflammation — studies show transplanted PD microbiota or dysbiosis exacerbates α-syn pathology and motor deficits in models, and microbiome manipulations alter brain mitochondrial/oxidative states MGBA review (2020)Microbiome → mitochondria in PD mice.

2) Thrombin/PAR1 is a CNS inflammatory activator — thrombin extravasation or increased local thrombin activity activates PAR1 on glia, potentiates microglial pro-inflammatory signaling, and may contribute to neuronal injury; thus inhibiting thrombin/PAR1 is a mechanistic test to ask whether microbiome-driven peripheral inflammation funnels into CNS thrombin activity and aSyn processing PAR1 thrombin microglia.

3) Post-fibrillization C-terminal truncations of α-synuclein (notably fragments ending ~114) form rapidly after internalization and remodel fibril packing / interactome; proteomic mapping is essential to capture these species and to test whether thrombin-dependent CNS proteases (or microbiome-driven inflammation) change truncation patterns C-terminal truncation aSyn mapping.

Proteomics & fragments workflow (concise)

1. Separate insoluble/soluble fractions (SDS/Tx-100) and run 16% Tricine gels to resolve low-MW truncations (as in truncation studies).
2. Cut bands (HMW and low-MW), in-gel digest (trypsin, GluC), LC-MS/MS (Orbitrap Lumos) and top-down LC-MS for intact proteoforms; search with Mascot/SEQUEST/MS-Amanda and MaxLFQ quantitation as in published datasets (aSyn proteomics methods).
3. Quantify relative abundance of full-length vs truncated proteoforms (report 1–140, 1–119, 1–114, 1–103, and any novel N-terminal or NAC-region fragments) and compare groupwise (A–D). Link specific fragment abundances to TH counts and thrombin activity by regression.

Predictions & decision rules (pre-registered)

• If PD-constipation FMT increases peripheral Th17 and plasma IL-17A vs control-FMT (p<0.05) and increases brain thrombin activity, we interpret this as microbiome → peripheral Th17 → CNS thrombin axis candidate.
• If thrombin inhibitor normalizes CNS thrombin activity and reduces the abundance of C-terminal truncation fragments (e.g., 1–114) and rescues TH+ neuron counts vs PD-FMT + vehicle, interpret as thrombin (or downstream proteases regulated by thrombin signaling) contributing to fragment formation and neurodegeneration.
• If aSyn truncation patterns change (higher 1–114 in PD-FMT group) and correlate (R>0.5) with CNS thrombin activity and Th17 levels, this supports the hypothesized multi-step pathway; absence of correlation would challenge it.

Potential confounders & controls

• Antibiotic pre-treatment can alter immune baseline — include antibiotic-only controls or allow microbiome recovery before PFF to minimize antibiotic-immune confounds (caveat: many FMT PD-model studies use brief antibiotic depletion; interpret carefully) P. merdae MPTP antibiotic-FMT study.
• Donor heterogeneity — pool multiple donors per group or use multiple independent donor pools and treat donor-pool as a blocking factor to avoid single-donor artifacts.
• Sex—this protocol focuses on males to match many PFF/time-course datasets; female cohorts should be tested separately due to sex differences in immunity and microbiome effects.

Key assays & recommended reagents

• Thrombin activity: chromogenic substrate S-2238 or validated fluorogenic thrombin activity kit; measure in brain lysates normalized to protein.
• PAR1 readout: qPCR and immunoblot for F2R (PAR1), and TRAP peptide stimulation in ex vivo microglia to test responsiveness (in vitro validation).
• α-syn fragment mapping: Tricine gels, N-term and C-term antibodies (SYN-1, 4B12, C-terminal specific clones), top-down LC-MS for intact proteoforms and LC-MS/MS peptide mapping per methods in truncation mapping papers aSyn truncation methods.

Limitations, blindspots and alternative interpretations

• Correlation ≠ causation: microbiome-driven Th17 increases and thrombin activity may be parallel effects rather than linear causation; the thrombin inhibitor arm is essential but may have off-target effects (choose selective, BBB-penetrant agents and validate).
• Proteases generating C-terminal truncations (calpains, cathepsins, AEP) may be regulated by calcium/oxidative stress rather than thrombin directly — if thrombin inhibition fails to reduce truncation, consider profiling calpain/cathepsin activities and EV-associated proteases (EVs cleave aSyn at E114 in another study) EV proteases cleave aSyn.
• Species differences: human PD-donor microbiota effects in mice may not fully replicate human disease; use multiple donors and validate engraftment and metabolite profiles (e.g., SCFAs, TMAO) which have been implicated in PD-associated metabolomic shifts Metabolome in ASO mice.

Data analysis plan (brief)

1. Primary comparisons: PD-FMT vs control-FMT (vehicle) for Th17, brain thrombin activity, aSyn fragment abundances, nigral TH counts (ANOVA + post-hoc; adjust p by Benjamini-Hochberg for multi-proteoform tests).
2. Assess thrombin inhibitor effect with interaction term (FMT*inhibitor) to test rescue; mediation analysis to test whether changes in thrombin mediate effect of FMT on aSyn truncation and TH loss.
3. Proteomics: adopt MaxLFQ label-free quantitation, require fragment identification by MS/MS, and report fragment-specific fold-changes with FDR-corrected p-values; deposit raw data to ProteomeXchange (PXD) and transcriptome to GEO as in prior studies.

What would disprove the core model?

• No difference in peripheral Th17 or plasma IL-17A between PD-FMT and control-FMT despite robust engraftment -> weakens the microbiome→Th17 link.
• PD-FMT increases Th17 but no increase in CNS thrombin activity and no change in aSyn truncation pattern -> suggests alternate peripheral-to-CNS pathways (e.g., vagal transport) rather than thrombin-mediated processing.
• Thrombin inhibitor reduces CNS thrombin activity but fails to alter aSyn truncation or dopaminergic loss -> indicates truncation and neurodegeneration are independent of thrombin (other proteases like calpains/cathepsins may dominate).

Essential citations used to build and justify this design

• C-terminal truncation aSyn study
• PAR1-thrombin microglial activation
• LAG3/Treg PFF model
• EV proteases cleave aSyn
• P. merdae FMN protects in MPTP model
• ASO metabolome & microbiome

Practical next steps

1. Finalize donor inclusion/exclusion (PD+constipation phenotype) and prepare 2 independent donor pools per arm to avoid single-donor effects.
2. Pilot FMT engraftment (n=3 per donor-pool) to confirm colonization and targeted metabolite shifts (e.g., SCFAs, TMAO) before running full PFF experiment.
3. Pre-register the precise primary endpoints (e.g., Th17 fold-change, brain thrombin activity, 1–114 proteoform fold-change, SN TH stereology) and statistical analysis plan.